Your session is about to expire
← Back to Search
ARV-1801(ACG-701) Active Group for Cystic Fibrosis (REPRIEVE Trial)
REPRIEVE Trial Summary
This trial will assess a new oral drug's effectiveness and safety in treating Cystic Fibrosis-related lung flare-ups, compared to a placebo.
- Cystic Fibrosis
REPRIEVE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowREPRIEVE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.REPRIEVE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA accepted ARV-1801/ACG-701 Active Group for medicinal use?
"The safety of ARV-1801/ACG-701 Active Group was rated a 2, as there is some data to back up its safety but not yet enough evidence supporting its efficacy."
What number of participants has joined this research effort?
"Affirmative. Clinicaltrials.gov reveals that this medical trial, initiated on February 10th 2023, is actively searching for participants. 80 test subjects are needed from 2 healthcare centres."
Are researchers presently recruiting participants for this research project?
"Affirmative, the information on clinicaltrials.gov suggests that this medical experiment is actively seeking participants. The trial was uploaded to the website on February 10th 2023 and revised for accuracy lastly on February 14th of the same year. 80 individuals are needed across 2 sites for successful completion of this investigation."
Share this study with friends
Copy Link
Messenger